Serotonin 1B Receptor Modulates Frequency Response Curves and Spectral Integration in the Inferior Colliculus by Reducing GABAergic Inhibition

Laura M. Hurley, Jo Anne Tracy, and Alexander Bohorquez

Department of Biology, Indiana University, Bloomington, Indiana

Submitted 7 May 2008; accepted in final form 16 July 2008

INTRODUCTION

Neuromodulatory signals such as serotonin are broadly released in the brain in response to changes in internal state (Trulson and Jacobs 1979, 1981) but transform the response properties of sensory neurons in highly specific ways (Hurley et al. 2004; Mooney et al. 1996; Xiang and Prince 2003). This specificity is achieved through the targeting of classes of neurons by a variety of receptor types that may alter intrinsic neuron properties or target presynaptic neurons and alter the release of neurotransmitter (Hoyer et al. 1994, 2002). One consequence of these effects is that serotonin can alter the balance of different types of inputs within sensory regions. For example, serotonin may alter the balance between ascending versus descending projections (Mooney et al. 1996) or the balance between within- versus between-layer communication in the cortex (Xiang and Prince 2003).

In the inferior colliculus (IC), an auditory midbrain nucleus, serotonin modifies a number of response properties, including both spectral and temporal aspects of evoked auditory responses (Hurley and Pollak 2005; Hurley et al. 2002). One of the properties of IC neurons that has been the best studied in terms of its modulation by serotonin is frequency tuning, which can be expanded or narrowed by serotonin (Hurley and Pollak 2001). Frequency response curves in the IC are often shaped by inhibition, which may narrow the range of frequencies and intensities that evoke action potentials and decrease the level of responses within the excitatory curve itself (Fuzessery and Hall 1996; Hall 1999; Lu and Jen 2001; Palombi and Caspary 1996; Suga 1965; Yang et al. 1992). In addition to regions near the excitatory frequency response curve, tones at frequencies that are distant from the excitatory curve by an octave or more also decrease or facilitate excitatory responses (Mittman and Wenstrup 1995). These phenomena are simply inherited from lower auditory nuclei for many neurons (Portfors and Wenstrup 2001) but are influenced by the convergence of excitatory and inhibitory inputs within the IC for other neurons (Sanchez et al. 2008). The effect of any serotonergic mechanism that regulated excitatory-inhibitory balance would therefore be likely to affect not only frequency tuning but also broader spectral sensitivity in the IC.

Of the multiple types of serotonin receptor present in the IC (Cornea-Hebert 1999; Harlan et al. 2000; Heidmann et al. 1998; Morales et al. 1998; Peruzzi and Dut 2004; Thompson et al. 1994; To et al. 1995; Vilaró et al. 2005), the 5-HT1B receptor has the potential to regulate the excitatory-inhibitory balance that shapes spectral sensitivity in a highly targeted way. This is because the 5-HT1B receptor is localized near presynaptic terminals and in axons and decreases the release of a variety of neurotransmitters (Bennett-Clarke et al. 1993; Chadha et al. 2000; Hwang and Dun 1999; Johnson et al. 1992; Matsuoka et al. 2004; Sari 2004; Stanford and Lacey 1996). Co-localization of the 5-HT1B receptor with a subset of GABAergic neurons in the IC suggests that this receptor could diminish intrinsic inhibitory inputs, although the 5-HT1B receptor is also observed in the cell bodies of non-GABAergic neurons (Peruzzi and Dut 2004). Furthermore, local activation of this receptor in the IC usually increases stimulus-evoked responses and in some neurons also increases the bandwidth of excitatory responses (Hurley 2006). The similarity of these effects to the effects of drugs that antagonize inhibitory transmission in the IC, particularly GABAergic transmission through GABA_A receptors (Fuzessery and Hall 1996; Hall 1999; LeBeau et al. 2001; Lu and Jen 2001; Palombi and Caspary 1996; Suga 1965; Yang et al. 1992) suggests a testable
hypothesis that 5-HT1B activation decreases inhibition of IC neurons.

The goals of this study were to better define both the functional consequences and mechanisms of 5-HT1B receptor activation in frequency tuning and spectral integration within the IC. To accomplish this, the selective 5-HT1B agonist CP93129 was iontophoretically applied to IC neurons in vivo, and its effects on excitatory-inhibitory balance were characterized across a broad spectral range. Excitatory-inhibitory balance was assessed with two-tone stimuli in which a fixed-frequency tone that evoked spikes was presented together with a second variable-frequency tone that could reduce the response to the first tone. Although such a reduction in response may have multiple sources along the auditory pathway, including mechanical properties of the cochlea (Pickles 1982; Ruggiero et al. 1992), or intrinsic and synaptic properties of neurons in the IC or lower auditory nuclei, the local application of drugs allowed the local regulation of these two-tone interactions to be examined. To explore a possible link between the 5-HT1B receptor and GABAergic pathways, the effects of 5-HT1B activation were compared with the effects of GABA\textsubscript{A} receptor blockade in the same neurons, both in sequence and during co-application. If activation of the 5-HT1B receptor decreases the release of GABA that subsequently activates GABA\textsubscript{A} receptors, then its effects should be similar to those of GABA\textsubscript{A} antagonists and reducible by application of GABA\textsubscript{A} antagonists. Our results are consistent with the hypothesis that the 5-HT1B receptor reduces GABAergic inhibition as one mechanism of action, and that the result is a modulation of the spectral responsiveness of IC neurons.

**METHODS**

**Experimental subjects and surgical techniques**

Twenty-three male CBA/J mice of 3–8 wk of age were used in this study. Surgical procedures for mice were similar to those described previously for Mexican free-tailed bats (Hall and Hurley 2007). Mice were briefly anesthetized with isoflurane fumes, then injected intra-peritoneally with 120 mg/kg ketamine and 5 mg/kg xylazine. Once mice were briefly anesthetized with isoflurane fumes, then injected intraperitoneally, they were injected with 0.1 M NaCl and had resistances of 8–20 MΩ. Pipettes were connected by a silver-silver chloride wire to a Dagan 2400 amplifier (Minneapolis, MN). Spikes were fed through a spike signal enhancer (FHC; Bowdoinham, ME) before being digitized through a data-acquisition processor board (Microstar; Bellevue, WA). Iontophoresis pipettes were broken to a tip diameter of 10–20 μm with the single-barreled recording pipette protruding 10–15 μm in front of the multibarreled pipette. Multibarreled electrodes were positioned above the IC under visual control through a dissecting microscope and lowered with a piezoelectric microdrive (Burleigh/EXFO inchworm, Mississauga, Ontario) until action potentials were observed. The top of the IC was defined as the point of initial contact of the recording electrode to ground.

**Auditory stimuli**

Auditory stimuli were created and data were collected with the custom software package Batlab (Dr. Donald Gans, Kent State University). Stimuli were regulated in intensity through a PA5 attenuator and were filtered through an FT-6 antialias filter (TDT; Alachua, FL). Stimuli were played through either an earphone biased with 200 V DC (Schuller 1997), positioned in the ear contralateral to the recording electrode, or a midline freefield speaker (Infinity Emit B, Harman International Industries; Woodbury, NY). The frequency response of the custom-made earphone was flat ±6 dB from 10 to 120 kHz with harmonic distortions ≥34 dB below the fundamental frequency. Calibration of the freefield speaker was accomplished by placing a measuring microphone (ACO Pacific S9200 kit; Belmont, CA) in the position occupied by the mouse’s head during experiments. The response of the speaker was flat within ±6 dB from 13 to 40 kHz, and harmonic distortions were 30–40 dB below the fundamental frequency across this range, which encompassed the characteristic frequencies of 68% of recorded neurons. The speaker produced a higher intensity of sound at lower frequencies.

Tone bursts of 20 ms in duration and 0.5-ms rise and fall times were used to measure frequency tuning and decreases in spikes in two-tone paradigms. Frequency tuning was measured by presenting tones across the frequency ranges of single neurons from 10 dB below threshold to 30–50 dB above threshold at characteristic frequency (CF). The frequency intervals of the presented tones varied from 1 to 5 kHz, depending on the bandwidth of the neuron recorded. Two-tone protocols were used to measure the decreases or increases of tone-evoked spikes by the presentation of a second tone. To generate two-tone stimuli, an excitatory probe tone was presented at a neuron’s CF. The probe tone was set at 10–30 dB (mean ± SE) above the minimum threshold of a given neuron. To measure the frequency dependence of two-tone effects, a test tone was then varied in frequency and presented at the same onset time and for the same duration as the probe tone. Test frequencies ranging from 2 to ±50–70 kHz were presented when a contact with a neuron was first established, and frequency regions evoking decreases or increases in spikes relative to the probe alone were assessed. Measurements of control and drug effects were then tailored to include these regions of interest. Because neurons were not sampled with uniform increments of test frequencies, regions that showed only mild effects of the test tone may have been missed. This focus on regions of interest was necessary for presenting test stimuli during multiple control and drug conditions while the neural recordings were maintained. Test tones were presented 10–20 dB (mean ± SE) above probe tones, to maximize inhibition. For a subset of 54 neurons, the time of onset of the probe tone was varied relative to that of a test tone at the frequency producing the maximal two-tone spike reduction, to generate delays between the two tones ranging from −20 ms (probe tone leading by 20 ms) to +40 ms (probe tone lagging by 40 ms).

**Extracellular recording of single neurons**

A total of 126 single IC neurons were recorded through extracellular glass pipettes attached in a “piggy-back” configuration (Havey and Caspary 1980) to a tribarreled micropipette used for the iontophoresis of drugs. The single-barreled recording pipettes were filled with 1 M NaCl and had resistances of 8–20 MΩ. Pipettes were connected by a silver-silver chloride wire to a Dagan 2400 amplifier (Minneapolis, MN). Spikes were fed through a spike signal enhancer (FHC; Bowdoinham, ME) before being digitized through a data-acquisition processor board (Microstar; Bellevue, WA). Iontophoresis pipettes were broken to a tip diameter of 10–20 μm with the single-barreled recording pipette protruding 10–15 μm in front of the multibarreled pipette. Multibarreled electrodes were positioned above the IC under visual control through a dissecting microscope and lowered with a piezoelectric microdrive (Burleigh/EXFO inchworm, Mississauga, Ontario) until action potentials were observed. The top of the IC was defined as the point of initial contact of the recording electrode to ground.
Responses to stimuli were measured before, during, and after the iontophoresis of drugs through the multibarreled pipette of the piggyback electrode. Two of the pipette barrels were filled with receptor agonists or antagonists, and one was filled with 1 M NaCl to serve as a sum channel, balancing the iontophoretic currents ejected through the other barrel. The barrels were connected by silver-silver chloride wire to iontophoresis pump modules (Dagan Ion-100). The selective 5-HT1B agonist CP93129 dihydrochloride and the nonselective 5-HT antagonist methysergide maleate (both from Tocris Biosciences; Ellisville, MO) were used to activate and block the 5-HT1B receptor, respectively. Although multiple auditory response properties are altered by anesthetics, including ketamine/xylazine anesthesia (Astl et al. 1996), the effect of CP93129 itself is not statistically distinguishable in animals that are under maintenance ketamine/xylazine anesthesia versus awake (Hurley 2006). Either bicuculline methiodide (Sigma-Aldrich; St. Louis, MO) or SR95531 hydrobromide (galbazine; Tocris Bioscience) was used to block GABA_A receptors. All drugs were dissolved at 10 mM in 200 mM NaCl, pH 4.5. This vehicle solution does not alter neural responses when iontophoresed alone (Hurley and Pollak 1999, 2001). Drugs were retained in the pipette with a negative current of 10–15 nA and ejected with positive current ranging from 10 to 80 nA. Drugs were ejected over a period of 5–10 min while their effects were monitored through the repetition of a small portion of the stimulus repertoire. When the spike counts stabilized, data were collected for the drug treatment. Similar procedures were followed for the collection of data for multiple drug and recovery conditions for each neuron.

Quantification and analysis

The effects of drugs on spike count, frequency bandwidth, and responses to two-tone stimuli were all measured. *Spike counts* were measured at CF, 10–30 dB above threshold. Spike counts during drug application were normalized to the spike counts before drug application and expressed as the proportional change in spike count [(drug – control)/control] or as the log value of the change [log(drug/control)]. Frequency response curves were generated by varying tones in frequency at a fixed intensity of 20–30 dB above the threshold at CF. Frequency bandwidth was measured as the difference between the low- and high-frequency borders of the response curves. Borders were determined by a linear interpolation between the frequencies evoking spike counts above and below the half-maximum value per 32 stimulus repetitions. Drug-evoked changes in bandwidth were expressed as the difference between drug and control values, in octaves. Decreases in spikes evoked in the two-tone protocol were measured as the *two-tone ratio*: the difference between the response evoked by the combination of the probe and test tones and the probe tone alone, normalized to the response evoked by the probe tone alone [(both tones – probe)/probe]. Negative two-tone ratio values indicate a reduction in spikes by the test tone relative to the probe tone alone, and positive values indicate an increase in spikes relative to the probe tone alone. The effects of drugs on the two-tone ratio were expressed as a simple difference (drug-control), so that positive values indicate that the test tone evoked a smaller decrease in spikes in the presence of a drug. None of the effects of CP93129 on these response characteristics was correlated with the age of individual mice (in days) at the time of experimentation (Pearson’s correlations, *P* = 0.237 for spike count, *P* = 0.75 for bandwidth, and *P* = 0.91 for 2-tone ratio, *n* = 19 mice).

Spike data were exported from Batlab in ASCII format for statistical analysis. Differences in the effects of different drug treatments on the measurements above were assessed either with ANOVAs or t-tests using Excel (Microsoft; Redmond, WA) or Statistica (StatSoft Inc; Tulsa, OK). Correlations among different drug treatments, or of a single drug treatment on different neural response properties, across the neuron population were assessed with Pearson’s product-moment correlations.

**RESULTS**

To measure the responses of IC neurons to the activation of the 5-HT1B receptor in vivo, a total of 126 single neurons were recorded extracellularly through high-resistance glass micropipettes from the IC of 23 male CBA/J mice. The selective 5-HT1B agonist CP93129 was iontophoresed during the recording of all 126 neurons through a multibarreled pipette attached to the recording pipette in piggyback configuration (Hayev and Caspary 1980). Responses of neurons to tone bursts were recorded before, during, and after the application of CP93129. Here we first present evidence that the specific patterns of effects of CP93129 on frequency tuning and two-tone interactions vary among IC neurons, but that these effects are similar to those evoked by a removal of inhibition. We further test whether the effects of CP93129 are consistent with a GABAAergic mechanism.

**CP93129 increases evoked responses**

CP93129 usually increased spike counts evoked by the presentation of tone bursts. A typical effect of CP93129 is illustrated in Fig. 1A, the peristimulus time histograms of the response of a single IC neuron to a 20-ms tone burst at the neuron’s CF of 29 kHz. The number of spikes fired by the neuron approximately doubled during the application of CP93129, largely through an increase in spikes in the latter part of the spike train. The co-application of methysergide, a nonselective 5-HT receptor antagonist, in conjunction with CP93129 (CP+ meth), blocked the increase in spikes. After drug application was stopped, the neuron maintained close to the control level of response. This type of increase in sound-evoked responses was common among IC neurons as illustrated by the histogram in Fig. 1B, which shows the distribution of CP93129-evoked changes in the response to a tone at CF, 10–30 dB above threshold. Values are expressed as the log of proportional changes in spike count [log(CP/control)] due to an extensive diminishing “tail” of neurons with large increases in spike count. The dashed line represents the point of no change in spike count, filled bars are increases in spike count, and open bars are decreases in spike count. In all, 61% of neurons (77/126) increased their spike count by over 30%, a criterion used to assess serotonergic effects in previous studies (Hall and Hurley 2007; Hurley and Pollak 1999). In contrast, relatively few neurons responded to CP93129 by decreasing their evoked spikes by 30% or more (5/126).

Methysergide was applied not only onto the neuron in Fig. 1A but also onto 16 additional neurons. Of these, 14 neurons significantly increased their average spike count in CP93129 (*P* < 0.05, 2-tailed unpaired t-test); methysergide significantly reduced this effect in 9 of the 14 neurons. Figure 1B, inset, shows the average proportional change in spike count evoked by CP93129 alone versus the change in spike count evoked by the concurrent application of CP93129 and methysergide, both relative to predrug values. CP93129 increased the spike count in this group of 17 neurons by 40.0% on average when applied alone, but only by 15.7% when co-applied with methysergide. This difference was significant (*P* = 0.007, 2-tailed paired t-test).

**CP93129 expands frequency responses in some neurons**

To determine how CP93129 alters frequency tuning in mice, we measured the effects of CP93129 on frequency response curve bandwidth for 83 neurons. For some neurons, CP93129...
facilitated responses at all frequencies similarly without changing the range of frequencies that evoked a response. For other neurons, however, CP93129 not only facilitated spikes, but also expanded the excitatory frequency range. Both types of effects are illustrated in Fig. 2A, which consists of frequency response curves, or isointensity plots of mean spike count (±SE) versus frequency, for two different neurons. Neuron 1 had relatively broad tuning, with responses ranging from 12 to 24 kHz at 30 dB above the neuron’s threshold at CF. CP93129 facilitated the spike count across this entire range. For neuron 2, CP93129 not only increased the spike count but also unmasked responses to tones that evoked little or no response in the control, changing the overall shape of the response curve. Neither neuron was held for long enough to obtain a recovery frequency response curve.

The effects of CP93129 on frequency tuning were quantified by measuring the bandwidth of the frequency response curve as the difference between the frequencies marking the low and high borders of the curve at 10–30 dB above the neurons’ thresholds at CF. Frequency response curve borders were calculated by a linear interpolation between the frequencies that evoked spike counts below and above the value of half of the maximum spike count. An example of this half-maximum bandwidth is shown for the upper neuron of Fig. 2A as bars stretching across the half-maximum value for the two tuning functions. Although CP93129 greatly facilitated the spike count for this neuron, its half-maximum bandwidth remained relatively unchanged. For the lower neuron, it is evident that the half-maximum bandwidth would increase in the presence of CP93129. Figure 2B compares proportional changes in spike count with changes in bandwidth in the set of 83 neurons for which frequency response curves were measured; the gray point represents an extreme value. Because CP93129-evoked changes in both spike count and bandwidth were usually positive, many data points are in the upper right quadrant of the plot. Within this quadrant, however, there is substantial spread in the data, emphasizing the variation in response patterns among neurons.

Effects of CP93129 are consistent with a decrease in inhibitory neurotransmission

Because inhibitory inputs cannot be measured directly through extracellular recording techniques, we performed two types of experiments to further test the hypothesis that CP93129 decreases inhibition within the IC. The first type of
experiment was to visualize inhibition indirectly through a decrease in response to an excitatory tone evoked by a second tone, and to measure the effect of CP93129 on responses to these so-called two-tone stimuli. A second type of experiment was to apply CP93129 while simultaneously blocking GABA<sub>A</sub> receptors, and quantitatively compare the effects of the two drugs both in sequence and during co-application.

**CP93129 has varied effects on two-tone spike reduction**

Similar to the effects of CP93129 on frequency bandwidth, this drug had variable effects on responses to two-tone stimuli. Figure 3 illustrates two neurons in which CP93129 increased evoked responses but did not remove specific regions of two-tone spike reduction. Two-tone frequency response curves representing the response to the co-presented probe and test tones are plotted as mean spike count (±SE) versus the test frequency for responses to 32 repeated stimulus presentations. The excitatory probe frequency is indicated by an asterisk, and the responses evoked by the probe tone alone in the control and different drug treatments are indicated by horizontal lines.

**Neuron 1** represents a relatively simple case. For this neuron, the probe was fixed at the neuron’s CF of 10 kHz, and the test tone was varied in steps of 1 kHz from 5 to 15 kHz. In the control, regions in which the test tone decreased responses relative to the probe tone occurred both above and below the CF of 10 kHz. In the presence of CP93129, the level of the response increased proportionally across the entire range of test frequencies. This is illustrated by the plots of the two-tone ratio at 9 and 12 kHz. CP93129 did not change the two-tone ratio at 9 or 12 kHz despite the overall increase in evoked responses, thus maintaining the relative spectral selectivity of this neuron.

In contrast, the effect of CP93129 on the two-tone frequency response curve of **Neuron 2** varied with test frequency. For this neuron, the probe was fixed at the neuron’s CF of 29 kHz, and the test tone was varied in steps of 2 kHz from 10 to 30 kHz. Test tones of 18 and 20 kHz produced a pronounced notch of spike reduction in the control. CP93129 decreased the two-tone ratio at frequencies above and below this notch. CP93129 did not reduce the notch at 18–20 kHz, however, and the two-tone ratio at 18 kHz did not vary much in any drug treatment. These effects of CP93129 resulted in a change of the spectral selectivity of the neuron with a greater contrast between the spike reduction at 18–20 kHz and the relative facilitation at other frequencies. The co-application of methysergide reversed this pattern of effects.

For some neurons, CP93129 did attenuate specific regions of two-tone spike reduction as demonstrated by the neuron in Fig. 4. For this neuron, CP93129 increased the spike count in the two-tone curve and decreased the spike reduction in a region ranging from 6 to 10 kHz (Fig. 4A). CP93129 also decreased the two-tone spike reduction at higher frequencies, but to a lesser extent, as seen by comparing the two-tone curve and two-tone ratios in the control versus CP93129 at 8 and 14 kHz. This correlated with the single-tone frequency response curve of the same neuron (Fig. 4B) in which tuning expanded into lower-frequency regions during CP93129 application. These findings suggest that CP93129 decreased the two-tone reduction of spikes in a frequency-specific manner for this neuron with a larger effect at frequencies lower than the control best frequency.

**Effects of CP93129 vary across the neuron population**

Figure 5, a plot of the two-tone ratio in the control versus during CP93129 application for 111 neurons that showed any amount of two-tone spike reduction, illustrates two key points of the effects of CP93129 across the neuron population. The first of these is that CP93129 usually decreased the two-tone ratio when it had an effect, consistent with a decrease in inhibition. This can be seen by the large number of neurons above the dashed line marking a slope of unity (m = 1). A second important point illustrated in this plot is that the effects of CP93129 varied substantially among neurons. Many neurons showed small or intermediate changes in the two-tone ratio, resulting in a relatively continuous distribution of shifts.
in the ratio. The effects of CP93129 across different response properties also varied. This was measured across the neuron population by performing a Pearson’s correlation on the effects of CP93129 on two-tone ratio (drug-control), bandwidth of frequency response (difference in octaves), and spike count (drug-control)/control). The only significant correlation among these variables was between CP93129-evoked changes in spike count and two-tone ratio ($P \leq 0.005$), but the correlation itself was relatively low ($r \leq 0.32$).

**CP93129 has qualitatively similar effects at different probe-test delays**

Figure 5 illustrates responses to two-tone stimuli in which the two tones were presented simultaneously and overlapped completely. IC neurons show a peak in two-tone reduction of spikes when tones are simultaneously presented (Nataraj and Wenstrup 2005). Two-tone suppression in the cochlea could make a relatively large contribution to the response to such simultaneously presented tones, as opposed to nonsimultaneously presented tones, because cochlear suppression has a rapid onset and decay relative to synaptic inhibition (Arthur et al. 1971; Suga et al. 1975). This raises the concern that events in the IC, and the effects of the local application of CP93129, could make a correspondingly weak contribution to the two-tone interactions we observed. To explore this issue, stimuli incorporating a variable delay between the probe and test tones, ranging from $-20$ ms (probe tone leading) to $+40$ ms (probe tone lagging), were presented to 54 neurons to determine whether the effect of CP93129 was weaker with simultaneous tone presentation. The average two-tone decrease in spikes in the control was greatest at a delay of 0 ms, when the 20-ms probe and test tones were presented simultaneously and overlapped completely, but was also apparent at other probe-test delays (Fig. 6, black line, mean $\pm$ SE). CP93129 decreased the average two-tone ratio at probe-test delays at and around zero ms (Fig. 6, dashed black line, mean $\pm$ SE), as indicated by positive values of the difference between the ratio in CP93129 and the control (Fig. 6, gray line, right ordinate, mean $\pm$ SE). This finding illustrates that the local application of CP93129 has similar effects when tones were simulta-
neuron 1, CP93129 increased the total spike count, and gabazine had an even larger effect. Unlike neuron 1, the increase in spike count evoked by both CP93129 and gabazine was accompanied not only by an increase in the duration of the spike train but also by a decrease in the first-spike latency and the interspike interval. Thus for both neurons 1 and 2, the effects of CP93129 mimicked the effects of GABA_A antagonists not only on the spike count but on the timing of spikes within the spike train.

Figure 7B illustrates changes in evoked spike counts in the presence of either CP93129 (x axis) or one of the GABA_A antagonists (y axis) across a set of 35 neurons at CF, 20–30 dB above threshold at CF. Filled circles represent neurons for which responses to CP93129 and a GABA_A antagonist alone were measured. For neurons not exposed to a GABA_A antagonist alone, responses to the co-application of a GABA_A antagonist and CP93129 are plotted (open circles). As seen for the individual neurons, the correlation between the effects of CP93129 and the GABA_A antagonists was highly significant (P < 0.001, Pearson’s correlation). Additionally, most data points fall above the dashed line marking a slope of 1 (labeled m = 1), indicating that spike counts were higher in the presence of a GABA_A antagonist than in the presence of CP93129 alone.

GABA_A antagonists had effects similar to those of CP93129 not only on spike count but also on half-maximum bandwidth and peak spike reduction. These effects are summarized in the scatterplots of Fig. 8. Figure 8A plots the change in bandwidth evoked by CP93129 versus bicuculline or gabazine alone (closed circles) or by a combination of a GABA_A antagonist and CP93129 (open circles). Across the population of 24 neurons for which bandwidth was measured in the presence of multiple drug combinations, the effects of CP93129 and GABA_A antagonists were significantly correlated (P < 0.001, Pearson’s correlation). Figure 8B shows the same relationship for drug-induced changes in the peak two-tone ratio. Similar to spike count and band-
width, the effects of CP93129 and GABA_A antagonists on peak spike reduction were significantly correlated ($P < 0.001$, Pearson’s correlation).

Table 1 summarizes the similarities between the effects of CP93129 and GABA_A antagonists on the evoked response properties illustrated in Figs. 7 and 8 and on three temporal response properties: the average first-spike latency, the average interval between the first and second spike (1st ISI) within a train, and the average interval between the second and third spike in a train (2nd ISI). Of these response properties, all show a significant correlation between the effects of CP93129 and the effects of a GABA_A antagonist alone or a GABA_A antagonist in the presence of CP93129 (Pearson’s correlations).

Co-application of GABA_A antagonist reduces response to CP93129

If CP93129 acts by reducing GABAergic transmission, a second prediction is that the presence of a GABA_A antagonist should reduce the effect of CP93129. To test this prediction, we compared the effects of a GABA_A antagonist and CP93129 alone to the effect of CP93129 in the presence of a GABA_A antagonist. Relatively few neurons ($n = 15$) were held through all of these drug manipulations, and this analysis was carried out only for measurements of spike count because of the larger number of data points for this measurement relative to bandwidth and two-tone ratio. For this set of 15 neurons, the drug-evoked changes in spike count were measured at CF (bars in Fig. 9; asterisks denote significant difference from the CP93129-evoked change in spike count). The effects of a GABA_A antagonist alone, or of the combination of a GABA antagonist and CP93129, were significantly greater than for CP93129 alone, as expected from the scatterplots of Figs. 7 and 8B. The addition of CP93129 to a GABA_A antagonist did not lead to a further increase in spike count, however (repeated-measures ANOVA, df = 2, 28; $P = 0.005$ for the overall model; with least significant difference (LSD) post hoc tests $P = 0.007$ for CP93129 vs. a GABA_A antagonist, $P = 0.003$ for CP93129 vs. the drug combination, $P = 0.738$ for a GABA_A antagonist vs. the drug combination). In addition to this repeated-measures comparison, drug treatments were compared by examining subsets of neurons that were exposed to two of the three drug treatments. The similarities between treatments were then assessed with paired $t$-tests. This breakdown of drug treatments yielded 17 neurons that were exposed to both CP93129 and GABA_A antagonists alone, 33 neurons exposed to CP93129 alone versus the drug combination, and 16 neurons exposed to GABA_A antagonists alone versus the drug combination. The results for these pairs of drug treatments were similar to those for the smaller set of neurons. That is, the effect of CP93129 was significantly different from treatment with a GABA_A antagonist ($P = 0.013$, 2-tailed paired $t$-test) and from treatment with the drug combination ($P = 0.004$, 2-tailed paired $t$-test), but the effects of the GABA_A antagonist and the drug combination were similar ($P = 0.402$, 2-tailed paired $t$-test). Thus the effects of GABA_A antagonists and CP93129 were strongly subadditive on average consistent with action at different points along the same inhibitory pathway.

**TABLE 1. Correlation between CP93129 and GABA antagonists**

<table>
<thead>
<tr>
<th>Response Property</th>
<th>$n$</th>
<th>$r$ Value</th>
<th>$P$ Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spike count</td>
<td>35</td>
<td>0.60</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>0.5 max bandwidth</td>
<td>24</td>
<td>0.72</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Two-tone ratio</td>
<td>32</td>
<td>0.65</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>First-spike latency</td>
<td>30</td>
<td>0.42</td>
<td>0.02</td>
</tr>
<tr>
<td>First ISI</td>
<td>30</td>
<td>0.76</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Second ISI</td>
<td>22</td>
<td>0.90</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Across-population correlation between the effects of CP93129 and GABA_A antagonists on multiple response properties of inferior colliculus neurons. ISI, interspike interval.

**DISCUSSION**

The data presented here support two main conclusions on the role of the 5-HT1B receptor in the IC. First, our findings are consistent with the 5-HT1B receptor acting to decrease the release of GABA. Second, activation of the 5-HT1B receptor causes changes in frequency response curves and on spectral integration that vary widely across the neuron population. In the following discussion, we summarize the logic supporting a GABAergic mechanism of action of the 5-HT1B receptor, consider alternate mechanisms of action, and describe functional implications of the regulation of frequency sensitivity by this receptor.
In addition to the 5-HT1B receptor, several other types of neuromodulatory receptor are capable of altering GABAergic transmission in the IC (Ma et al. 2002; Tongjaroenbong et al. 2004; Yigit et al. 2003), or have anatomical associations with GABAergic neurons (Kalyuzhny et al. 2000; Peruzzi and Dut 2004; Tongjaroenbong et al. 2006). These studies underscore that the 5-HT1B receptor is one of multiple neurochemical mechanisms likely to regulate inhibition within the IC, although these other mechanisms have not been explored in terms of their regulation of frequency responsiveness.

Potential additional mechanisms of 5-HT1B action

We focused on the GABA<sub>A</sub> receptor because of its well-studied relationship to frequency tuning in the IC, and our results support the GABA<sub>A</sub> receptor as one pathway for the effects of the 5-HT1B receptor. Our results do not preclude additional effector mechanisms of 5-HT1B activation not tested in this study, however. In fact, a logical additional consequence of 5-HT1B activation decreasing GABA release would be to decrease the activation of GABA<sub>B</sub> as well as GABA<sub>A</sub> receptors. In the IC, activation of the GABA<sub>B</sub> receptor has an inhibitory effect and block of the GABA<sub>B</sub> receptor has an excitatory effect on auditory responses, although these effects are relatively modest (Burger and Pollak 1998; Faingold et al. 1989; Vaugn et al. 1996). Thus a decrease of GABA<sub>B</sub> receptor activation could potentially contribute to the overall increase in excitability we observed during application of the 5-HT1B agonist. The 5-HT1B receptor itself, in addition to being a heteroreceptor on nonserotonergic neurons, acts as an autoreceptor on serotonergic fibers in several brain regions, leading to a diminished release of serotonin (Roberts et al. 2001; Sari 2004). It is therefore possible that a decrease in the activation of a serotonin receptor with inhibitory effects could have accounted for some of the effects of 5-HT1B activation. One such receptor is the 5-HT1A receptor, which often hyperpolarizes neurons (Barnes and Sharp 1999; Hoyer et al. 2002). Activation of this receptor within the IC does in fact induce widespread decreases in auditory responses (Hurley 2006, 2007). A final possibility that has not been excluded is that the 5-HT1B receptor reduces glycnergic inhibition, which also shapes frequency tuning (LeBeau et al. 2001; Lu and Jen 2001). The presence of any of these additional mechanisms of 5-HT1B activation in the IC would raise the interesting possibility that this receptor regulates the balance of multiple signaling pathways through targeted presynaptic effects.

Functional implications of 5-HT1B modulation

SEROTONERGIC CONTEXT INFLUENCES THE EFFECT OF THE 5-HT1B RECEPTOR. The functional consequences of 5-HT1B activation will depend on a large extent on the conditions during which serotonin is released and on the other infrastructure of the serotonergic system within the IC. Because the release of serotonin is not triggered by auditory stimuli in the same way as inhibitory inputs, the function of the 5-HT1B receptor is not likely to be the simple opposite of the function of the inhibition it reduces. Serotonergic neurons that innervate the IC, located outside the auditory system in the dorsal and median raphe nuclei (Klepper and Herbert 1991), have higher rates of firing during waking than during sleeping states (Trulson and Jacobs

Evidence that the 5-HT1B receptor regulates inhibition

Activation of the 5-HT1B receptor decreases the release of a variety of neurotransmitters among different regions of the brain (Bennett-Clarke et al. 1993; Chadha et al. 2000; Hwang and Dun 1999; Johnson et al. 1992; Matsuoka et al. 2004; Stanford and Lacey 1996; Sari 2004). Although a definitive conclusion that 5-HT1B activation decreases GABA release would require measuring GABA release directly or monitoring synaptic activity in vitro, the in vivo results described here are all consistent with activation of the 5-HT1B receptor in the IC reducing GABAergic inhibition. This conclusion is based on four types of evidence resulting from selectively activating the 5-HT1B receptor. The first of these is that 5-HT1B activation caused an increase in sound-evoked responses and in some neurons an expansion in the excitatory frequency response curve. These phenomena have now been observed in both Mexican free-tailed bats (Hurley 2006) and in mice, suggesting that the role of the 5-HT1B receptor is similar in the IC of these divergent model animals. Second, 5-HT1B activation often attenuated and in some cases abolished the reduction of an excitatory response by a second stimulus. Third, 5-HT1B activation and GABA<sub>A</sub> blockade had remarkably similar effects both in single neurons and across populations of neurons. This was true not only for the direction and magnitude of the responses, but also for frequency response bandwidths, two-tone effects, and interspike intervals. Finally, blocking GABA<sub>A</sub> receptors reduced the facilitation of spike count by the 5-HT1B agonist, so that the effects of 5-HT1B activation and GABA<sub>A</sub> blockade were subadditive. An important feature of all of these effects of the 5-HT1B receptor is that they varied widely among neurons as do the effects of blocking GABA<sub>A</sub> receptors (Fuzessery and Hall 1996; Lu and Jen 2001; Palombi and Caspary 1996; Suga 1965; Yang et al. 1992). This implies that the functional consequences of receptor activation similarly vary among neurons.

FIG. 9. Comparison of the effects of GABA<sub>A</sub> antagonists alone vs. GABA<sub>A</sub> antagonists and CP93129. Average changes in spike count at CF relative to the control are presented for a set of 15 neurons that were recorded for long enough for the sequential application of all 3 drug treatments. Spike count changes in the presence of a GABA<sub>A</sub> antagonist alone, or in the presence of a combination of a GABA<sub>A</sub> antagonist and CP93129, were each significantly greater than for CP93129, but not significantly different from each other (repeated-measures ANOVA, P = 0.005 overall, df = 2, 28; with post hoc LSD tests, P = 0.007 for CP93129 vs. GABA<sub>A</sub> antagonist alone, P = 0.003 for CP93129 vs. drug combination, P = 0.738 for GABA<sub>A</sub> antagonist alone vs. drug combination). * significant difference from the CP93129-evoked change in spike count.
1979, 1981), presumably correlated with an increase in serotonin level in the IC across this behavioral transition. Serotonin levels also fluctuate in some brain regions in response to social stimuli or stressful situations (Boutelle et al. 1990; Clement et al. 1998; Mas et al. 1995). Measurements of serotonin levels within the IC show activation of the serotonergic system in response to systemic injection of salicylate (Liu et al. 2003), but not following a 45-min exposure to white noise (Cransac et al. 1998), although small increases in serotonin levels have been measured during the presentation of broadband noise as well as during waking from anesthesia (Hall and Hurley 2007).

In general, the effects of 5-HT1B activation are likely to be greatest during internal states or situations evoking a high level of behavioral arousal.

Another important contextual consideration is the presence of additional types of serotonin receptors in the IC. Members of at least four families of serotonin receptor have been localized within the IC (Cornea-Hebert 1999; Harlan et al. 2000; Heidmann et al. 1998; Morales et al. 1998; Peruzzo and Dut 2004; Thompson et al. 1994; To et al. 1995; Vilarnò et al. 2005), but the effects of only a few of these on auditory responses have been measured. Other than the 5-HT1B receptor, the best-characterized serotonin receptor is the 5-HT1A receptor, which usually has a somatodendritic localization (Barnes and Sharp 1999; Hoyer et al. 2002). In keeping with its hyperpolarizing effect in other brain regions, activation of this receptor usually decreases the overall auditory responsiveness of IC neurons (Barnes and Sharp 1999; Hoyer et al. 2002; Hurley 2006, 2007). Because both the 5-HT1A and the 5-HT1B receptors have a relatively high affinity for serotonin (Hoyer et al. 1994), they should both be activated with increasing levels of serotonin. Because both 5-HT1A and 5-HT1B agonists affect relatively large proportions of the neuron population (Hurley 2006, 2007), it seems reasonable to predict that they affect the same neural circuits in at least some cases. This has never been directly assessed, however, nor has whether these receptors act in opposition to each other or interact in complementary ways.

Is variability in the effects of the 5-HT1B receptor functional?

Variability among neurons in the effects of 5-HT1B activation was observed at multiple levels in the current study, including variation in the specific pattern of effects across the frequency response curves (Figs. 2–4), and even whether neurons responded to 5-HT1B activation at all (Figs. 1, 2, and 5). Activation of the 5-HT1B receptor caused complex patterns of reduction in inhibition that should influence responses to spectrally rich signals such as vocalizations in neuron-specific ways. Perhaps the simplest type of response transformation observed was for neurons that did show changes in response level without accompanying changes in frequency response curve bandwidth (Fig. 2A, top neuron) or in relative two-tone spike reduction (Fig. 3, neuron 1). Because changes in the responses of IC neurons to vocalizations are correlated with changes in frequency tuning (Klug et al. 2002; Hurley and Pollak 2005), these neurons would be expected to maintain their relative selectivity for spectrally complex signals despite a higher overall response level. In contrast, other types of changes in frequency tuning or spectral integration would be expected to alter the selectivity for complex signals in ways that would match their spectral content and temporal structure (Nataraj and Wenstrup 2006; Portfors 2004; Portfors and Wenstrup 1999; Taniguchi et al. 1986). For example, the neurons that exhibited expansions of their frequency response curves (Fig. 2A, lower neuron) would be expected to show an increase in response to vocalizations containing these unmasked frequencies. Similarly, for neurons in which discrete notches of spike reduction were unchanged despite a general increase in spikes (Fig. 3, neuron 2), a greater contrast might emerge between the reduced responses to stimuli containing these “notch” frequencies relative to the facilitation of those that do not.

Another type of variation was simply that 5-HT1B activation decreased two-tone effects for some neurons but not others. Because differences among the patterns of response to 5-HT1B activation may be influenced by differences in inputs or intrinsic properties among the neurons themselves, it is tempting to speculate that these different classes of neurons, and their responses to 5-HT1B activation, also fulfill distinct functional roles. An interesting comparison exists in visual cortex, in which different classes of inhibitory neurons can be distinguished not only on the basis of their spike waveforms but also by their differential sensitivity to serotonin receptor agonists (Xiang and Prince 2003). A higher proportion of fast-spiking interneurons than low-threshold spike interneurons are sensitive to the 5-HT3 receptor, whereas a higher percentage of low-threshold spike interneurons are sensitive to the 5-HT1A receptor. Because these receptors have opposite effects on neuron excitability, the effects of serotonin application on the sIPSCs received by pyramidal neurons are complex. In many systems, neurons targeted by the 5-HT1B receptor can also be projection neurons arising from particular sources. For example, in the nearby superior colliculus, retinotectal projections, as opposed to corticotectal projections, express the 5-HT1B receptor (Mooney et al. 1994, 1996), potentially regulating the balance between ascending and descending inputs in vivo. Likewise during development of the somatosensory and visual systems, thalamocortical neurons express the 5-HT1B receptor, potentially contributing to the patterning of barrel cortex (Bennett-Clarke et al. 1993; Leslie et al. 1992). Indeed, in frog optic tectum, manipulation of the 5-HT1B receptors of projections from retinal ganglion cells disrupts the topographic map of the tectum (Butt et al. 2002). Whether classes of inhibitory inputs with differential sensitivity to 5-HT1B activation are further distinguished by their physiological characteristics or nuclei of origin in the IC, however, is not yet known.

Implications for plasticity

A final interesting possibility is a role for the 5-HT1B receptor in plasticity in frequency tuning, which occurs in the IC in response to associative learning, or acoustic damage related to trauma or aging (Barsz et al. 2007; Bartels et al. 2007; Felix and Portfors 2007; Gao and Suga 1998; Turner et al. 2005). This possibility arises because changes in inhibition have been implicated in such plasticity, whether it expressed in a widespread way across the tonotopic map of the IC or is associated with targeted changes in tonotopy, as in associative learning or tinnitus (Bartels et al. 2007; Gerken 1996; Wang et al. 1996, 2002; Willott 1988; Xiao and Suga 2002). Suggestively, several serotonin receptors have already
been implicated in learning-related frequency tuning plasticity (5-HT2A) (Ji and Suga 2007) or are regulated in level in frequency 5-HT2C receptors in central auditory pathways. ARO Abstr 23; 113, 2000.


LeBeau FE, Malmierca MS, Rees A. Iontophoresis in vivo demonstrates a key role for GABA(A) and glycine in shaping frequency response areas in the inferior colliculus of guinea pig. J Neurosci 21: 7303–7312, 2001.


